RXRX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RX

Mkt Cap

$1.86B

Volume

38.85M

Next Earnings

November 4th

Loading chart

RX

RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock

RXRX

Pay with—

Available Balance0.00

RX

Mkt Cap

$2.23B

Volume

38.85M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to NoteRecursion Pharmaceuticals (RXRX) fell 8.03% in the latest trading session, significantly underperforming the S&P 500's 0.06% decline. Despite a 36.25% gain over the past month, the stock has received a Zacks Rank #4 (Sell) rating. The company faces headwinds with consensus EPS estimates revised 2.17% lower over the past month, though revenue projections show growth. The biotech sector itself ranks in the bottom 33% of industries.Zacks Investment Research · Oct 12, 2026

Tempus AI Expands Strategic Collaborations to Drive Future GrowthTempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold.Zacks Investment Research · Oct 12, 2026

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for InvestorsRecursion Pharmaceuticals (RXRX) declined 3.14% to $4.63 on October 6, 2026, underperforming the broader market which gained modestly. Despite a strong 31.68% monthly gain, the stock fell as the S&P 500 rose 0.58%. The company is expected to report an EPS of -$0.24 with revenue of $8.42 million, showing improvement year-over-year. RXRX holds a Zacks Rank #3 (Hold) rating with recent downward EPS estimate revisions.Zacks Investment Research · Oct 6, 2026

AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS InsiderThe global AI in pharmaceutical market is projected to grow from USD 3.07 billion in 2025 to USD 48.43 billion by 2035, with a CAGR of 31.76%. The U.S. market is expected to reach USD 15.10 billion and Europe USD 12.60 billion by 2035. Growth is driven by generative AI, adaptive trials reducing patient enrollment by 40%, regulatory endorsement including FDA's qualification of AIM-NASH, and increased venture capital investment in AI-first drug discovery platforms.GlobeNewswire Inc. · Sep 7, 2026

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS InsiderThe global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.GlobeNewswire Inc. · Sep 7, 2026

The Market Just Told You Which Layer Of AI Biology It Is Paying ForRecent earnings in life sciences technology reveal that the market is rewarding companies with proprietary data and systems of record over those selling software or AI models alone. Veeva Systems beat expectations with strong AI product adoption, while Certara missed on modest software growth and Recursion Pharmaceuticals fell short on revenue expectations. MindWalk Holdings, which owns curated biological data infrastructure, is positioned to benefit from this trend with its HYFT Technology and newly launched ReefIQ platform, though it remains unprofitable with modest recurring revenue.GlobeNewswire Inc. · Sep 3, 2026

AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma PlayersArtificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.GlobeNewswire Inc. · Aug 25, 2026

AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision MedicineArtificial intelligence is fundamentally restructuring bioinformatics, compressing drug discovery timelines and attracting billions in venture capital. AI tools like AlphaFold and generative biology platforms are delivering measurable ROI, with companies achieving 99% cost reductions in drug discovery. North America leads adoption, supported by federal programs and substantial R&D investments from established life sciences players.GlobeNewswire Inc. · Aug 6, 2026

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesRecursion's Compensation Committee approved the grant of 3,234,866 inducement restricted stock units to 24 new employees on July 27, 2026, as part of its 2024 Inducement Equity Incentive Plan. The awards will vest quarterly over four years, subject to continued employment.GlobeNewswire Inc. · Jul 31, 2026

3 Stocks With the Most Upside by the End of 2026The article identifies three stocks with significant upside potential by end of 2026: CRISPR Therapeutics, expected to generate $40M in revenue this year and $160M+ next year as its Casgevy treatment gains traction; Microsoft, trading 40% below analyst price targets as management addresses cloud/AI business challenges; and Recursion Pharmaceuticals, an AI-driven drug discovery platform trading over 100% below analyst consensus with multiple developmental milestones approaching.The Motley Fool · Jul 30, 2026

to start trading

RX

RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock

RXRX

Pay with—

Available Balance0.00

Your PositionYou don't own any RXRX yet.

Related Tickers

Earnings